Emergent BioSolutions gets late-stage MAb cancer therapy from TenX BioPharma

Emergent BioSolutions (NYSE: EBS) has acquired from fellow USA-based TenX BioPharma the rights to zanolimumab, an investigational, late-stage monoclonal antibody cancer therapy targeting T-cell lymphomas.

Under the terms of the deal, TenX BioPharma received a $2.5 million upfront in cash. In addition, Emergent will pay TenX BioPharma up to $5.5 million if certain development milestones are achieved and royalties on future products sales to third parties.

Emergent acquired worldwide rights to all oncology, autoimmune and inflammatory disease indications for zanolimumab and will be responsible for all future costs of developing, manufacturing, and commercializing zanolimumab.